Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 65862-652

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 65862-652). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Memantine Fig 1)

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Memantine Fig 1)
FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Fig 2)

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Fig 2)
FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Memantine Fig 3)

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Memantine Fig 3)
FDA Label Image

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Fig 4)

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Fig 4)
FDA Label Image

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Memantine Fig 5)

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Memantine Fig 5)
FDA Label Image

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Fig 6)

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Fig 6)
FDA Label Image

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Memantine Fig 7)

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Memantine Fig 7)
FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Fig 8)

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Fig 8)
FDA Label Image

Package Label-principal Display Panel (5 mg Blister Carton (10 x 10 Unit-dose))

Package Label-principal Display Panel (5 mg Blister Carton (10 x 10 Unit-dose))
This appears to be a label for Memantine Hydrochloride Tablets USP, containing information about dosage and storage conditions. The tablets are manufactured by Aurobindo Pharma and come in a package of 100 unit-dose tablets. The label also includes a list of ingredients and precautions for storage.*
FDA Label Image

Package Label-principal Display Panel (10 mg (60 Tablets Bottle))

Package Label-principal Display Panel (10 mg (60 Tablets Bottle))
This is a prescription drug with the name Memantine Hydrochloride. It is manufactured in India by Aurobindo Pharma USA, Inc. Each film-coated tablet contains 10 mg of memantine hydrochloride USP. The recommended dosage and full prescribing information can be found in the package insert. The tablets should be stored at controlled room temperature and dispensed in a tightly closed container as described in the USP. The NDC code for this product is 65862-653-60.*
FDA Label Image

Package Label-principal Display Panel (10 mg Blister Carton (10 x 10 Unit-dose))

Package Label-principal Display Panel (10 mg Blister Carton (10 x 10 Unit-dose))
The text appears to be a label of medication called "Memantine Hydrochloride Tablets USP". The medication comes in packages containing 20 tablets with a dosage strength of 10 mg. The label also includes instructions for storage and usage.*
FDA Label Image

Package Label-principal Display Panel (5 mg (60 Tablets Bottle))

Package Label-principal Display Panel (5 mg (60 Tablets Bottle))
NDG 65862-652go E26h is a medication in tablet form that contains mg of memantine hydrochloride USP. It is distributed by Aurabindo Pharma USA, Inc and manufactured in India. The usual dosage is specified on the packaging for Lot MO and the medication is only available with a prescription. The medication should be stored at room temperature between 20° to 25°C (68° to 77°F). The medication should be kept out of the reach of children. The text includes a printing zone coding area and dotted lines that should not be printed.*
FDA Label Image

Memantine Structure (Memantine Str)

Memantine Structure (Memantine Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.